Insulet: Strong Q4 Execution and Encouraging 2026 Outlook Offset by Valuation and Competitive Pressures, Justifying Hold Rating

In a report released today, Mathew Blackman from TD Cowen maintained a Hold rating on Insulet, with a price target of $294.00.

Mathew Blackman has given his Hold rating due to a combination of factors, including Insulet’s strong fourth quarter performance and a solid initial 2026 outlook that modestly exceeded expectations. The company posted record new patient starts, with a notable contribution from type 2 diabetes users, and quarterly revenue that grew sharply year over year and surpassed both guidance and Street forecasts.

At the same time, he anticipates that the stock’s valuation could pull back following the results, tempering the near‑term upside despite the operational strength. Growing competitive pressures in the insulin delivery market also limit conviction for a more aggressive stance, leading him to maintain a neutral, or Hold, recommendation on the shares rather than moving to a more bullish rating.

In another report released on February 4, TipRanks – xAI also downgraded the stock to a Hold with a $274.00 price target.

Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is neutral on the stock.